Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report)'s stock price traded down 6.2% on Wednesday . The company traded as low as $24.23 and last traded at $24.23. 6,732 shares were traded during mid-day trading, a decline of 89% from the average session volume of 61,093 shares. The stock had previously closed at $25.82.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. assumed coverage on shares of Ascentage Pharma Group International in a report on Thursday, March 27th. They issued an "overweight" rating for the company.
Check Out Our Latest Report on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Up 3.4%
The business's 50 day simple moving average is $22.70.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new position in Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International at the end of the most recent reporting period.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Featured Articles
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
